Velodyne Lidar Introduces Velabit™
7.1.2020 23:00:00 EET | Business Wire | Press release
Velodyne Lidar, Inc. today introduced Velabit™, Velodyne’s smallest sensor which brings new levels of versatility and affordability to 3D lidar perception, at CES 2020. The Velabit leverages Velodyne’s innovative lidar technology and manufacturing partnerships for cost optimization and high-volume production. The sensor advances Velodyne’s mission to make high-quality 3D lidar sensors readily accessible to everyone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005849/en/
Velabit™, Velodyne Lidar’s smallest sensor, brings new levels of versatility and affordability to 3D lidar perception. (Photo: Velodyne Lidar)
The Velabit perfectly complements Velodyne’s sensor portfolio. The sensor delivers the same technology and performance found on Velodyne’s full suite of state-of-the-art sensors and will be the catalyst for creating endless possibilities for new applications in a variety of industries. The compact Velabit can be embedded almost anywhere within vehicles, robots, unmanned aerial vehicles (UAVs), infrastructure and more. It is designed to be easy to manufacture at mass production levels.
The Velabit is engineered to be an optimal automotive grade lidar solution for Advanced Driver Assistance Systems (ADAS) and autonomous vehicles. It enables robust perception coverage for Blind-Spot Monitoring, Cross Traffic Detection, Automatic Emergency Braking, and Pedestrian and Bicyclist Safety. Highly configurable for customer application, this mid-range sensor can be combined with other Velodyne lidar sensors, such as the Velarray™, for high-speed operation or function as a standalone lidar solution in low-speed applications.
The Velabit addresses the cost, safety and design challenges of autonomous solutions while delivering strong sensor performance. Here are the Velabit’s leading features:
- Integrated processing in a compact size of 2.4” x 2.4” x 1.38” – smaller than a deck of playing cards – to be easily embedded in a wide range of solutions.
- Range up to 100 meters.
- Outstanding field of view (FoV): 60-degree horizontal FoV x 10-degree vertical FoV.
- Highly configurable to support a range of applications.
- Proven, Class 1 eye-safe 903 nanometer technology.
- Bottom connector with cable length options.
- Multiple manufacturing sources scheduled to be available for qualified production projects.
“The Velabit democratizes lidar with its ultra-small form factor and its sensor pricing targeted at $100 in high-volume production, making 3D lidar available for all safety-critical applications,” said Anand Gopalan, Chief Executive Officer, Velodyne Lidar. “Its combination of performance, size and price position the Velabit to drive a quantum leap in the number of lidar-powered applications. The sensor delivers what the industry has been seeking: a breakthrough innovation that can jump-start a new era of autonomous solutions on a global scale.”
“Before the Velabit there was no suitable small and lightweight lidar for small unmanned aerial vehicles and unmanned ground vehicles performing obstacle avoidance or mapping,” said Alberto Lacaze, president, Robotic Research. “Since Robotic Research’s Pegasus Mini™ is a fully autonomous ground and air vehicle, it requires the Velabit’s size and versatility. In addition, the Velabit enables the most advanced GPS-denied HD mapping in the industry. The Velabit fills a much-needed space in the market and is currently in a class of its own.”
The Velabit will be available to customers mid-2020. Velodyne provides world-class technical support for the sensor across North America, Europe and Asia. It is now on display at Velodyne Lidar’s CES 2020 booth located at the Las Vegas Convention Center North Hall – booth #7520.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005849/en/
Contact information
Sean Dowdall
Landis Communications Inc. for Velodyne Lidar, Inc.
(415)
286-7121
velodyne@landispr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
